イマチニブ療法後の消化管間質腫瘍患者におけるIDRX-42（GSK6042981）とスニチニブの比較試験

基本情報

NCT ID

NCT07218926

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

450

治験依頼者名

GlaxoSmithKline

概要

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.

対象疾患

介入

依頼者（Sponsor）